The NeoTRACK Trial – Neoadjuvant TiRagolumab, Atezolizumab and Chemotherapy – Dissection of IO efficacy in NSCLC by longitudinal tracKing: a non-randomized, open-label, single-arm phase II study

Status

Suspended

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-501322-38-00

Acronym

NeoTRACK

Enrollment

Registered

2023-03-30

Start date

2023-05-26

Completion date

Unknown

Last updated

2025-10-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer (NSCLC)

Brief summary

• Major pathological response (MPR) rate after curative intent surgery

Interventions

DRUGTiragolumab

DRUGATEZOLIZUMAB

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
• Major pathological response (MPR) rate after curative intent surgery	—

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026

­­­­­The NeoTRACK Trial – Neoadjuvant TiRagolumab, Atezolizumab and Chemotherapy – Dissection of IO efficacy in NSCLC by longitudinal tracKing: a non-randomized, open-label, single-arm phase II study